Artemether Does Not Turn α Cells into β Cells

Area of Science:

• Endocrinology
• Cell Biology
• Diabetes Research

Background:

• Pancreatic alpha cells exhibit plasticity and can potentially transdifferentiate into beta cells.
• Artemether, an antimalarial, was proposed to promote alpha to beta cell transdifferentiation by suppressing the Arx transcription factor.
• Previous studies relied on indirect evidence and cell lines, lacking direct demonstration of this conversion.

Purpose of the Study:

• To investigate whether artemether promotes the transdifferentiation of primary pancreatic alpha cells into beta cells.
• To evaluate the effects of artemether on primary beta cell function.

Main Methods:

• Experiments using primary pancreatic islet cells.
• Assessment of cell transdifferentiation markers.
• Measurement of insulin expression (Ins2), glucose uptake, calcium signaling, and insulin secretion in response to glucose.

Main Results:

• Artemether did not induce transdifferentiation of primary alpha cells into beta cells.
• Artemether significantly reduced Ins2 expression in primary beta cells (>100-fold).
• Artemether suppressed glucose uptake and abrogated glucose-stimulated calcium responses and insulin secretion in beta cells.

Conclusions:

• Artemether does not promote alpha to beta cell transdifferentiation.
• Artemether appears to induce general dedifferentiation of islet endocrine cells.
• The use of artemisinins for promoting alpha to beta cell transdifferentiation in diabetes treatment is questionable.